Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MBOT vs MYO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MYO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–6 Matrix Metrics)

MYO Overall Winner 6-Pillar Tally: MBOT 1 – 4 MYO (1 Tie) Matrix Metrics: MBOT 6 – 4 MYO

As of Nov 20, 2026, Myomo Inc. (MYO) is the stronger overall head-to-head candidate over Microbot Medical, Inc. (MBOT) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MBOT carries a Unified Composite Score of 54.9/100 (HOLD) at $0.68 (31.8x Forward P/E, -5057.2% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin).

  • Composite vs. Pillar Nuance: While MBOT currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. MYO 40.1/100 SELL), MYO captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-21.8% vs. -5057.2% operating margin) and revenue trajectory (+22.2% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: MBOT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MBOT vs MYO
MBOT NASDAQ
Microbot Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.68
-8.52% 1D
Market Cap $49.9M
TTM Revenue $418,000
Forward P/E 31.8x
Beta / 30D Vol 1.68β · 145% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 48.0 Fund 55.0 Flow 68.0 Mom 49.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.8%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $0.97 · SMA50: $1.09
MYO NYSE American Head-to-Head Winner
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32

6-Pillar Scorecard Institutional Category Breakdown (MBOT 1 – 4 MYO)

Columns: Metric · MBOT · MYO
1. Valuation Multiples MBOT
Forward P/E 31.8x N/M
Trailing P/E 31.8x N/M
PEG Ratio 0.70x N/M
EV / Revenue 115.9x 0.9x
2. Growth & Scale MYO
Revenue Growth (YoY) +0.0% +22.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $418,000 $46M
Market Cap $49.9M $33.7M
3. Profitability & Quality MYO
Gross Margin N/A 70.1%
Operating Margin -5057.2% -21.8%
Net Profit Margin 0.0% -33.1%
Return on Equity (ROE) -26.3% -173.5%
4. Balance Sheet & Cash Flow MYO
Cash Generation (TTM) -$20M -$9.1M
Cash Flow Margin N/A -20.0%
Net Cash / Leverage $1.5M Net Cash $8.9M Net Debt (3.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYO
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 112.5% (30th %ile) 266.0% (81st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MBOT (6) vs MYO (4)
Institutional Metric MBOT MYO Criterion Row Edge
Market Capitalization
Scale
$49.9M $33.7M Larger Scale MBOT
Trailing P/E Ratio
Valuation
31.8x N/M Lower Multiple MBOT
Forward P/E Ratio
Valuation
31.8x N/M Lower Multiple MBOT
Revenue Growth (YoY)
Growth
+0.0% +22.2% Higher Growth MYO
Operating Margin (TTM)
Profitability
-5057.2% -21.8% Higher Margin MYO
Net Profit Margin
Profitability
0.0% -33.1% Higher Margin MBOT
Return on Equity (ROE)
Capital Efficiency
-26.3% -173.5% Higher ROE MBOT
52-Week Range Position
Momentum
7% ($1–$3) 16% ($1–$2) Stronger Trend MYO
Beta / 30D Volatility
Risk Regime
1.68β · 145% Vol 2.22β · 107% Vol Lower Realized Risk MYO
Unified Institutional Score
Composite Signal
54.9 / 100 (HOLD) 40.1 / 100 (SELL) Higher Composite MBOT
Trailing 12M Revenue (USD)
Operating Scale
$418,000 $46M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 70.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.70x PEG · 115.9x EV/Rev N/M PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$20M ($1.5M Net Cash) -$9.1M ($8.9M Net Debt (3.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBOT +5.71 pp
MBOT: -27.81% · MYO: -33.52%
3M Horizon MYO +12.4 pp
MBOT: -54.05% · MYO: -41.65%
6M Horizon MYO +38.21 pp
MBOT: -60.23% · MYO: -22.02%
1Y Horizon MYO +76.88 pp
MBOT: -64.58% · MYO: +12.3%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MBOT Revenue MYO Revenue MBOT Op. Margin MYO Op. Margin Margin Leader
FY2018 N/A $0M N/A -430.8% MYO
FY2019 N/A $0M N/A -281.3% MYO
FY2020 N/A $10M N/A -138.5% MYO
FY2021 N/A $10M N/A -74.1% MYO
FY2022 N/A $20M N/A -68.6% MYO
FY2023 N/A $20M N/A -42.8% MYO
FY2024 N/A $30M N/A -19.1% MYO
FY2025 N/A $40M N/A -35.2% MYO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MBOT BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 112.5%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MBOT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MBOT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $49.9M market capitalization and -5057.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MBOT vs MYO Key Questions & Quantitative Answers

As of Nov 20, 2026, Myomo Inc. (MYO) is the stronger overall head-to-head candidate over Microbot Medical, Inc. (MBOT) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MBOT carries a Unified Composite Score of 54.9/100 (HOLD) at $0.68 (31.8x Forward P/E, -5057.2% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin). Composite vs. Pillar Nuance: While MBOT currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. MYO 40.1/100 SELL), MYO captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-21.8% vs. -5057.2% operating margin) and revenue trajectory (+22.2% vs. +0.0% YoY). Technical & Structure Timing Caution: MBOT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MYO leads the Growth & Scale pillar: MBOT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $418,000 TTM revenue (N/A gross margin, -5057.2% operating margin), compared with MYO at +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MBOT cumulative revenue shifted N/A while MYO shifted +300.0%. In operating R&D and SG&A reinvestment, MBOT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MYO.

MBOT screens cheaper on headline valuation multiples. MBOT trades at 31.8x Forward P/E, 31.8x Trailing P/E, 0.70x PEG, and 115.9x EV/Revenue (unreported FCF margin), whereas MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBOT (-26.3% ROE) versus MYO (-173.5% ROE) capital efficiency.

In options market volatility and institutional positioning, MBOT carries 112.5% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 145% Vol realized risk). By comparison, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.